Skip to main content
. 2022 Nov 8;13:6740. doi: 10.1038/s41467-022-34495-z

Fig. 2. CD39i suppressed BC progression by increasing the CD45 + immune cell populations in tumor tissues.

Fig. 2

CD39i noteworthily inhibited the subcutaneous tumor growth (A, B) and improved the survival rate of mice (C), n = 10 for each group. The two-side unpaired Student’s t-test was used for the tumor size comparison of different groups at the same time point. The log-rank (Mantel–Cox) test was used to compare the survival curves. CD39i noteworthily reduced the maximum cross-sectional area (Mean ± SEM: 0.2050 ± 0.0359 vs. 0.0675 ± 0.0202) of the orthotopic mouse bladder tumor, n = 4 for each group (D, E) and the bladder weight (Mean ± SEM: 0.6333 ± 0.0494 vs. 0.2000 ± 0.0447) of mice, n = 6 for each group (F, G). The two-side unpaired Student’s t-test was used for two-group comparisons of values. Flow cytometry analysis showed that CD39i treatment induced a significant increase in immune cell infiltration within the tumor tissues, including CD45 + cells (H, I), CD4 + and CD8 + T cells (J–L). Mean ± SEM: I 4.598 ± 0.1262 vs. 10.05 ± 0.3638, K 2.277 ± 0.3334 vs. 4.958 ± 0.0859, L 3.782 ± 0.4524 vs. 6.598 ± 0.5756. All the flow cytometry analyses were repeated 3 times with 5 samples in each group. M The single cells from subcutaneous tumors (3 subcutaneous tumors from 3 mice mixed 1:1:1) of the control and CD39i groups were clustered into 9 major cell types. N There was no difference in the proportion of the cell clusters between the control and CD39i groups. Source data are provided as a Source Data file (A, C, E, G, I, K, L). P-values <0.05 were considered significant: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.